Investigational Drug Laquinimod Helped Treat Lupus Nephritis in Phase 2 Trial
Wednesday, June 12, 2013
Results of a Phase 2 trial showed that the investigational drug laquinimod improved kidney function in patients with lupus nephritis. The data was reported today at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Madrid. Based on these positive results, a larger clinical trial of laquinimod in combination with standard of care (mycophenolate mofetil and corticosteroids), compared to standard of care alone, is planned among patients with lupus nephritis to further evaluate the safety and efficacy of the drug.
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms